Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Hickman M., Steer C., Tilling K. et al.
Addiction: 2018, 113(8), p. 1461–1476.
Please come back again soon. This entry is under construction.
Jones A., Pierce M., Sutton M. et al.
Addiction: 2017, 113(2), p. 279–286.
Substance use treatment commissioned on a payment-by-results basis in England has been linked to higher rates of in-treatment abstinence and non-injecting than other commissioning models, but lower rates of treatment initiation and completion. Is this enough to support the policy?
REVIEW 2017 HTM file
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate
Palpacuer C., Duprez R., Huneau A. et al.
Addiction: 2017, in press.
In 2013 nalmefene was authorised for moderating drinking among patients not in need of detoxification, extending pharmacotherapy to less dependent drinkers. Though uniquely authorised for this purpose, this review found other (and probably cheaper) drugs have been just as or possibly more effective, but for none was there high quality evidence.
Bird S.M., McAuley A., Perry S. et al.
Addiction: 2016, 111(5), p.883–891.
In 2011 Scotland became the first country to fund a national policy of distributing the opiate-blocker naloxone to prevent deaths involving opiate-type drugs. According to this evaluation it did prevent deaths where the effect was most likely to be seen – in the weeks after release from prison.
Champion K.E., Newton N.C., Stapinski L.A. et al.
Addiction: 2016, 111, p. 1396–1405.
An online course implemented in Australian secondary schools improved on standard health and drug education by reducing intentions to use new psychoactive substances and in the short-term increasing knowledge about these substances and about ecstasy.
Knai C., Petticrew M., Durand M.A. et al.
Addiction: 2015, 1000(8), p. 1217–1225.
At the heart of the UK government’s alcohol strategy are ‘Responsibility Deal’ pledges made by alcohol companies, but rather than being prompted by the deal, this report says actions committed to were usually already done or underway. Other sources suggest the process helped forestall a more effective measure – a minimum per unit price for alcohol.
Mason T., Sutton M., Whittaker W. et al
Addiction: 2015, 110(7), p. 1120–1128.
A flagship drug treatment policy initiative appears to have backfired in England, where the government’s pilot payment-by-results schemes seem to have led to fewer successful completions of treatment and more prospective patients declining treatment.
Knai C., Petticrew M., Durand M.A. et al.
Addiction: 2015, 1000(8), p. 1232–1246.
Even if fully implemented, pledges made by alcohol companies under the ‘Responsibility Deal’ for England would be unlikely to significantly affect consumption or health, judge the deal’s evaluators. Instead, other sources suggest they helped forestall a more effective measure – a minimum per unit price for alcohol.
REVIEW 2015 HTM file
A comparison of the efficacy of brief interventions to reduce hazardous and harmful alcohol consumption between European and non-European countries: a systematic review and meta-analysis of randomized controlled trials
Elzerbi C., Donoghue K., Drummond C.
Addiction: 2015, 10(7), p. 1082–1091.
Amalgamation of results from relevant studies finds that in high-income nations brief alcohol advice to emergency or primary care patients remains effective whether trials take place in European or non-European drinking cultures and health service contexts. Impacts were however small and may not be duplicated in routine practice.
Cousins G., Boland F., Courtney B. et al.
Addiction: 2015, 111, p. 73–82
Primary care methadone patients in Ireland were nearly four times more likely to die during periods out of treatment; the first few weeks after leaving were the peak risk period. The study’s support for unbroken, long-term treatment runs counter to recent UK government policy.
Select search results pageNEXT 1 2 3 4 5 6 7